Skip to main content

Search
Profile

Soheil Meshinchi, MD, PhD

|
Soheil Meshinchi, MD, PhD

Hematology-Oncology

On staff since September 2000

Academic Title: Associate Professor

Research Center: Center for Clinical and Translational Research

Recommendations

Be the first to recommend Dr. Soheil Meshinchi

Overview

Board Certification(s)
Pediatric Hematology-Oncology
Medical/Professional School
Wayne State University School of Medicine, Detroit
University of Michigan, Ann Arbor
Fellowship
Pediatrics, Wilmer Eye Institute / Johns Hopkins, Baltimore
Pediatric Hematology-Oncology, University of Washington School of Medicine, Seattle
Research Description

My clinical and research interests center around the treatment of pediatric myeloid leukemia. I am principal investigator on six research projects at Seattle Children's and Fred Hutchinson Cancer Research Center, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.

Research Focus Area

Cancer

Publications

Prognostic factors in pediatric acute myeloid leukemia.
Current hematologic malignancy reports , 2010 Oct: 200-6
C/EBP{alpha}-regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations.
Blood , 2010 Oct 1
Prognostic factors in pediatric acute myeloid leukemia.
Current hematologic malignancy reports , 2010 Oct: 200-6
C/EBP{alpha}-regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations.
Blood , 2010 Oct 1
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2010 Aug 5: 702-10
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2010 Aug 5: 702-10
MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2010 Aug: 248-53
MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Pediatric blood & cancer , 2010 Aug: 248-53
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
The lancet oncology , 2010 Jun: 543-52
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
The lancet oncology , 2010 Jun: 543-52
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood , 2010 Mar 25: 2372-9
Receptor tyrosine kinase alterations in AML - biology and therapy.
Cancer treatment and research , 2010: 85-108
Structural and functional alterations of FLT3 in acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2009 Jul 1: 4263-9
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood , 2009 Jun 25: 6558-66
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
British journal of haematology , 2009 Feb: 388-94
Structural and numerical variation of FLT3/ITD in pediatric AML.
Blood , 2008 May 15: 4930-3
Identification of genes with abnormal expression changes in acute myeloid leukemia.
Genes, chromosomes & cancer , 2008 Jan: 8-20
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
Blood , 2007 Aug 1: 979-85
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
Blood , 2007 Mar 15: 2314-21
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
The oncologist , 2007 Mar: 341-55
Clinical implications of FLT3 mutations in pediatric AML.
Blood , 2006 Dec 1: 3654-61
Clinical implications of FLT3 mutations in pediatric AML.
Blood , 2006 Dec 1: 3654-61
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood , 2006 Oct 15: 2764-9
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood , 2006 Oct 15: 2764-9
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Blood , 2006 Jul 1: 74-80
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
Blood , 2006 Jul 1: 400; author reply 400-1
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Blood , 2006 Jul 1: 74-80
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
Blood , 2006 Jul 1: 400; author reply 400-1
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
Blood , 2006 May 1: 3724-6
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.
Blood , 2004 Nov 15: 3058-63
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
Blood , 2004 Nov 1: 2646-54
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Pediatric blood & cancer , 2004 Oct: 571-9
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Blood , 2004 Mar 15: 2325-31
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
British journal of haematology , 2004 Feb: 481-4
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
Current oncology reports , 2003 Nov: 489-97
Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
British journal of haematology , 2003 Nov: 431-5
Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2003 Nov: 706-13
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Blood , 2003 Oct 1: 2387-94
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
Blood , 2003 Aug 15: 1474-9
Molecular targets in acute myelogenous leukemia.
Blood reviews , 2003 Mar: 15-23

Primary Office

Fred Hutchinson Cancer Research Center
FHCRC Box 358080 - MS D5-380
PO Box 19024
Seattle, WA 98109-1024
206-667-4077

Additional Offices

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options